跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2019/12/022244
CTRI/2019/12/022244已完成3 期

A multicentre, double-blind, randomized, single-period, placebo-controlled, parallel group study of Adapalene 0.1% and Benzoyl Peroxide 2.5% Topical Gel of BELUPO Inc., Croatia (Test) and Epiduo Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5%) (Reference) of Galderma (EU) in subjects with mild to moderate facial acne vulgaris

BELUPO Pharmaceuticals and Cosmetics Incorporated0 个研究点目标入组 650 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
650
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •1.Healthy male or non-pregnant female aged between >= 12 and <= 40 years with a clinical diagnosis of facial acne vulgaris
  • •2.Subject having >= 30 to <= 100 non-inflammatory lesions (i.e., open and closed comedones) and >= 20 to <= 50 inflammatory lesions (i.e. papules and pustules) and or <= 1 nodulocystic lesions (i.e., nodules and cysts) on the face which will be evaluated as per the Format of Appendix 4 by Principal investigator/Co-Investigator
  • •3.Subject having clinical diagnosis of facial acne vulgaris severity grade 2 or 3 as per IGA(Appendix7)
  • •4.Subject willing to refrain from use of all other topical acne medications or antibiotics during the 84 days treatment period
  • •5.Subject/ LAR/ parent/ guardian/ Impartial Witness willing to give their written informed consent and written informed assent (in case of subject < 18 years) to participate in the study
  • •6.Subject used the same brand of make-up for a minimum period of 2 weeks prior to randomization and willing to agree to not change the make-up brands or types during the study
  • •7.Females must use acceptable and effective methods of contraception such as the following:
  • •A)Sexual abstinence
  • •B)Double barrier method
  • •C)Intrauterine Device (IUD)
  • •D)Progestin Implant (i.e. Implanon or its equivalent)
  • •E)Oral contraceptives
  • •8.Medical history and physical examination without clinically relevant abnormalities
  • •9.All vital signs (i.e. blood pressure, body temperature, heart and respiration rate) within the normal range:
  • •systolic blood pressure: 100 - 140 mmHg
  • •diastolic blood pressure: 60 - 90 mmHg
  • •body temperature: for axillary readings [97°F (36.1°C) - 99°F (37.2°C)], or for oral readings [98°F (36.7°C) - 100°F (37.8°C)]
  • •heart rate (pulse): 60 - 100 bpm
  • •respiration rate: 12 - 20 breaths/min
  • •Blood pressure will be measured after the subject has rested for at least 5 minutes in supine position

排除标准

  • •1.Subject having presence of any skin condition that would interfere with the diagnosis or assessment of facial acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acne form eruptions caused by medications, steroid acne, steroid folliculitis or bacterial folliculitis)
  • •2. Subject having excessive facial hair (e.g. beards, sideburns, moustaches etc.) that would interfere with diagnosis or assessment of acne vulgaris as per the discretion of Principal investigator (PI)
  • •3. Subject with history of hypersensitivity or allergy to any medication (regardless the method of administration) and/or cosmetic product.
  • •4. Subject used oral retinoids (e.g. Isotretinoin) or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed) within 6 months prior to baseline
  • •5. Subject used estrogens or oral contraceptives for less than 3 months prior to baseline; use of such therapy must remain constant throughout the study
  • •6. Subject used cryodestruction or chemodestruction, dermabrasion, photodynamic therapy, acne surgery, intralesional steroids, or x-ray therapy on face within 1 month prior to baseline or planning to use during the study
  • •7. Subject used systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris (other than oral retinoids, which require a 6 month washout), systemic anti-inflammatory agents or immunosuppressive drugs within 1 month prior to baseline or planning to use during the study
  • •8. Subject used topical steroids, topical retinoids, topical acne treatments including over-the-counter preparations, topical anti-inflammatory agents, or topical antibiotics on the face within 2 weeks prior to baseline or planning to use during the study
  • •9. Subject used tanning booths, sunbathing or excessive exposure to the sun or planning to use during the study
  • •10. Subject with damaged skin on his/her face, either broken (cuts or abrasions), eczematous or sunburned.
  • •11. Subject who is planning to use spironolactone during the study
  • •12. Subject who had participated in another investigational drug or device research study within 30 days of enrolment
  • •13. Subject who used any medication or has any disease which in the judgment of the Investigator will interfere with the conduct or interpretation of the study
  • •14. Female subject who is pregnant, nursing or planning a pregnancy during the study
  • •15. Any reason for which, in the opinion of the Investigator, the subject should not participate in the study.

研究者

发起方
BELUPO Pharmaceuticals and Cosmetics Incorporated

相似试验

已完成
4 期
A multi-center, randomized, double-blind, double-simulated, positive drug parallel controlled clinical trial to evaluate the effectiveness and safety of Jiuwei Zhenxin Granules in the treatment of generalized anxiety disorderGeneralized Anxiety Disorder
ITMCTR2100004826Beijing Anding Hospital, Capital Medical University
尚未招募
4 期
A multi-center, randomized, double-blind, double-simulated, and positive-drug parallel-controlled clinical study to evaluate the effectiveness and safety of Quanduzhong capsule in treating essential hypertension&Essential hypertension (nephrasthenia syndrome)
ITMCTR2100004710Beijing Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 deviceMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2011-001825-25-DEovartis Pharma Services AG36
进行中（未招募）
不适用
A study to evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Indacaterol Maleate as a new formulation in the Concept1 deviceMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2011-001825-25-GBovartis Pharma Services AG36
进行中（未招募）
1 期
A randomized, multi-center, double-blind, double-dummy, parallel-group, 8 week pilot study, to investigate the effect of QMF Twisthaler® (250/400 µg q.d. evening) compared to fluticasone propionate/salmeterol (250/50 µg b.i.d.) FSC in patients with Chronic Obstructive Pulmonary Disease (COPD).Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD
EUCTR2008-000901-13-SKovartis Pharma Services AG